HK
INSY

Horizon Kinetics’s Insys Therapeutics, Inc. INSY Stock Holding History

Horizon Kinetics’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-44,207
Closed -$393K – 505
2017
Q3 		$393K Buy
44,207
+8,971
+25% +$92.6K 0.01% 387
2017
Q2 		$446K Buy
+35,236
New +$417K 0.01% 303

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Horizon Kinetics's INSY Position: Q4 2017 in Review

Horizon Kinetics sold out of Insys Therapeutics, Inc. (INSY) in Q4 2017, closing a stake of 44,207 shares — an estimated $393K sold.

Horizon Kinetics first reported a position in INSY in Q2 2017 and held it in 2 quarters. The position peaked at $446K in Q2 2017. 112 funds tracked by Wall St. Rank hold INSY as of Q4 2017.

  • Horizon Kinetics reported no remaining Insys Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Horizon Kinetics sold 44,207 Insys Therapeutics, Inc. shares in Q4 2017, an estimated $393K.
  • Horizon Kinetics first reported a position in Insys Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • Horizon Kinetics's Insys Therapeutics, Inc. position peaked at $446K in Q2 2017.
  • 112 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2017.

Based on Horizon Kinetics's 13F filing for Q4 2017, filed 14 Feb 2018.